AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00215514 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
Study NCT00613080 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: capecitabine
Description: 1650 mg/m\^2/day orally 5 days/week during radiotherapy.
Study NCT00613080 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: oxaliplatin
Study NCT00613080 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: resection
Description: All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
Study NCT00613080 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
Study NCT00613080 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOX
Description: Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m\^2, IV over 2 hours, day 1.~Leucovorin 400 mg/m\^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m\^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m\^2, IV continuous infusion over 46 hours, day 1.
Study NCT02226549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: LDV/SOF (90/400 mg) FDC tablet administered orally once daily
Study NCT03665129 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH5401 and Durvalumab
Description: IPH5401 and durvalumab
Study NCT02226549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VDV
Description: VDV 80 mg tablet administered orally once daily
Study NCT02226549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT01615601 — intervention group
Intervention type: DRUG
Intervention: darunavir (PREZISTA)
Description: Form = tablet, route = oral, Units = mg, number = 800 administered once daily
Study NCT01615601 — intervention group
Intervention type: DRUG
Intervention: etravirine (INTELENCE)
Description: Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
Study NCT01615601 — intervention group
Intervention type: DRUG
Intervention: ritonavir
Description: Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
Study NCT01615601 — intervention group
Intervention type: DRUG
Intervention: Other antiretroviral medications
Description: Given as per Canadian Product Monograph
Study NCT02608749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home care (HC)
Description: Home care (HC) group subjects were invited to LK site. For examining whether the exercise video could help elderly people to maintain their exercise and improve their muscle strength or not, the investigators provided exercise video to subjects, and encouraged them to play this exercise at least 2 hours for one week.
Study NCT03130842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sublingual alprazolam
Description: Patients receive one dose of oral formulation of alprazolam 0.5 mg for sublingual-administered at least 30 minutes before the procedure.
Study NCT03130842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral midazolam
Description: Patients receive one dose of intravenous formulation of alprazolam 7.5 mg for oral-administered (in syrup with apple juice) at least 30 minutes before the procedure.
Study NCT01522755 — intervention group
Intervention type: DEVICE
Intervention: Pacing system implant with the CapsureFix MRI pacing lead model 5086
Description: Pacing system implant with the CapsureFix MRI pacing lead model 5086
Study NCT03221244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VR Treatment
Description: Distractors
Study NCT03221244 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VR Active Control
Description: No distractors
Study NCT02015065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Vandetanib administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
Study NCT00483379 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: alglucosidase alfa
Description: intravenous infusion
Study NCT04923204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pharmacogenomic-testing with NEUROPHARMAGEN
Description: This observational retrospective study aims at evaluating the impact of the genetic variation in individual genes on the therapeutic response and side effects profile in a bipolar disorder cohort, using NEUROPHARMAGEN.~NEUROPHARMAGEN is a pharmacogenomic-based decision support tool that helps clinicians in the selection and dosing of psychoactive drugs based on the integration of pharmacogenetic information.
Study NCT01910090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET
Description: MULTI-LAYER TABLET
Study NCT01910090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ANTADYS® 100 mg, PEPCID® 20 mg
Description: ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
Study NCT00795938 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Single Dose of 50 mg Sildenafil Oral Tablet With Water
Study NCT00795938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Single Dose of 50 mg Sildenafil Experimental Tablet With Water
Study NCT00795938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
Study NCT02008981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcuma longa
Description: Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
Study NCT02008981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angelica sinensis
Description: Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
Study NCT02008981 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Siwu Tang
Description: TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
Study NCT02597127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-PCSSC
Description: ALN-PCSSC is a small interfering ribonucleic acid (RNA) that inhibits PCSK9 synthesis and is given as SC injections
Study NCT03216486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPS804
Description: IV administration of BPS804 in 5% Dextrose solution
Study NCT03571165 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: My Tools 4 Care - In Care
Description: Self-administered web-based transition toolkit (My tools 4 Care - In Care) contains interactive activities and resources to help carers through transitions.
Study NCT00787202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP- 690 550
Description: Administration via oral route twice daily for the duration of treatment
Study NCT00787202 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administration via oral route twice daily for the duration of treatment
Study NCT01442064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Description: Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
Study NCT01268917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: aspirin 100mg daily until the surgery day
Study NCT01268917 — intervention group
Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: aspirin
Description: aspirin is stopped 5-7 days before operation
Study NCT02316210 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrical stimulation
Study NCT03242018 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.
Study NCT03242018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet (identical to sotagliflozin 200 mg in appearance) orally, once daily.
Study NCT03242018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Sotagliflozin 200 mg, tablet, orally, once daily.
Study NCT02032641 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser treatment
Description: Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
Study NCT04148612 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Opti-Me
Description: Opti-Me algorithm provides the likelihood of response to the 3 treatment options: SSRIs, SNRIs or TMS in MDD patients.
Study NCT01555515 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implantation of autologous skin graft after ex-vivo treatment
Description: Subcutan implantation of autologous skin graft after ex-vivo treatment
Study NCT01555515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutan implantation of autologus skin graft after ex-vivo treatment
Description: Subcutan implantation of autologus skin graft after ex-vivo treatment
Study NCT04867941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: All study participants will receive a single oral dose of 50 mg ACP-196 (2 x 25 mg capsules) on Day 1 of the study.
Study NCT04336982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90009
Description: Injection
Study NCT04336982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet
Study NCT04336982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Injection
Study NCT04336982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Tablet
Study NCT02741882 — intervention group
Intervention type: OTHER
Intervention: Questionary
Description: Questionary with clinical, demographic and behavior outcomes at the pregnancy period
Study NCT03047018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program
Description: The CHANGE program is a a six-month long intervention consisting of 16 sessions. The first 10 sessions occur weekly while the remaining 6 sessions occur bi-weekly. Sessions last about 1 hour each. Nutrition intervention focuses on decreasing excess calories from liquids and solids and creating a balanced meal plan. Physical activity intervention uses fading strategies to increase participation in exercise. Behavior strategies promote success with meeting goals. Problem-solving techniques address challenges to adherence with implementing the program in the home setting. The standardized protocols include educational handouts, clinic-based activities and assessment procedures, and caregiver-directed homework and data collection.
Study NCT02258555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-9901
Description: GS-9901 tablets administered orally
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 10 mg BIW
Description: Participants received M4344 at a dose of 10 milligrams (mg) orally twice weekly (BIW) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 20 mg BIW
Description: Participants received M4344 at a dose of 20 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 40 mg BIW
Description: Participants received M4344 at a dose of 40 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 80 mg BIW
Description: Participants received M4344 at a dose of 80 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 160 mg BIW
Description: Participants received M4344 at a dose of 160 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 300 mg BIW
Description: Participants received M4344 at a dose of 300 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02597127 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Saline (sterile, normal, 0.9%) solution given as SC injections
Study NCT03738059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: will receive intravenous Dexmedetomidine
Study NCT03738059 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 0.9%
Description: will receive intravenous normal saline 0.9%
Study NCT03110445 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rVV-740CTA
Description: non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)
Study NCT04118907 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: multiple sensory stimulation
Description: The patients were recruited to record their medical history, and the hearing level, tinnitus indicators, vestibular function and tinnitus disability indicators were tested. Then the patients were randomly divided into six groups. They received the corresponding stimulation 20 minutes a day, 5 days a week for 3 weeks. After the last stimulation, the above tests were repeated immediately, one week later and three months later.
Study NCT04500340 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group CBT for test anxiety
Description: The cognitive-behavioral therapy protocol developed by Flaxman, Bond \& Keogh (2004) will be used as the intervention protocol. This protocol consists of 10 Sessions which are provided twice a week (each group will have 10 students).
Study NCT04147598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LFD
Description: Participants will receive daily prepared food trays to achieve a diet with approximately 10% of total fat, 1-5% of calories from saturated fat, and 5-9% of MUFA and PUFA. This diet will contain an approximate ratio of 1:1 of omega-6/omega-3 fatty acids.
Study NCT04147598 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAD
Description: Participants will receive daily prepared food trays to achieve a diet with approximately 35-40% of calories from fat, 10-11% of saturated fats, and 25-29% would be mono-unsaturated (MUFA) and PUFA. This diet will contain a 20-30:1 ratio of omega-6/omega-3 fatty acids, representing the current SAD.
Study NCT03050515 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
Study NCT04574440 — intervention group
Intervention type: DEVICE
Intervention: multichannel fNIRS monitoring
Description: Patients who will be enrolled in this study will be monitored during cardiac surgery using multichannel fNIRS monitoring. This consists of wearing the NIRS cap that will be positioned on the patient's head according to international operational guidelines and will be secured to the temporal region of the patient's forehead. The NIRS cap is entirely non-invasive and does not pose any additional risk to the patient. Monitoring will be commenced prior to the induction of anesthesia. Subsequent surgical and medical care will not be affected.
Study NCT00840489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin 1000-1200 mg qd for 24 weeks
Study NCT00840489 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: Colchicine 0.5 mg bd for 24 weeks
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 450 mg BIW
Description: Participants received M4344 at a dose of 450 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 700 mg BIW
Description: Participants received M4344 at a dose of 700 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 1050 mg BIW
Description: Participants received M4344 at a dose of 1050 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 1200 mg BIW
Description: Participants received M4344 at a dose of 1200 mg orally BIW until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 100 mg BID
Description: Participants received M4344 at a dose of 100 mg orally twice daily (BID) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 150 mg QD
Description: Participants received M4344 at a dose of 150 mg orally once daily (QD) until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 250 mg QD
Description: Participants received M4344 at a dose of 250 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 350 mg QD
Description: Participants received M4344 at a dose of 350 mg orally QD until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 400 mg
Description: Participants received M4344 at a dose of 400 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M4344 500 mg
Description: Participants received M4344 at a dose of 500 mg orally on Day 2 and Day 9 until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT02278250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Participants received intravenous infusion of Carboplatin at a dose of Area Under Curve5 (AUC5) on Day 1 of 21-day cycle until disease progression, death, unacceptable toxicity, new anticancer treatment was started, or study withdrawal.
Study NCT03775057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyDoseCoach app
Description: The intervention involves the use of the MyDose Coach application, which has been previously programmed with the following titration scheme according to fasting glucose.
Study NCT00845169 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forearm vascular study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
Study NCT00415103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant
Description: Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
Study NCT00651326 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate
Study NCT00651326 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy
Study NCT00415103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetrón: 0.25 mg iv every 48 hours, starting day 1